CORRECTION: Omixon, CHOP to Commercialize New HLA Genotyping Assay for MiSeq

Jun 04, 2014

|

This article has been corrected to list all of the genes targeted by the assay. The previous version noted only one of them.

NEW YORK (GenomeWeb) – Bioinformatics software firm Omixon today announced a licensing deal with the Children's Hospital of Philadelphia to commercialize a new next-generation sequencing-based HLA genotyping assay for use on Illumina's MiSeq instrument.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Years and Years

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Diving Evolution

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

This Week in Science

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

Issues to Overcome

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.

Jun

12

Featured Webinar

Bridging the Gap Between Testing and Treatment in Precision Oncology

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Main menu